Stock News

Blueprint Medicines (BPMC) Reaches $83.89 After 4.00% Down Move; King Luther Capital Management Has Cut By $1.08 Million Its Watsco (WSO) Holding

The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) is a huge mover today! The stock decreased 5.02% or $4.43 during the last trading session, reaching $83.89. About 248,425 shares traded. Blueprint Medicines Corporation (NASDAQ:BPMC) has risen 128.96% since December 12, 2016 and is uptrending. It has outperformed by 112.26% the S&P500.The move comes after 5 months negative chart setup for the $3.29B company. It was reported on Dec, 12 by Barchart.com. We have $80.53 PT which if reached, will make NASDAQ:BPMC worth $131.56M less.

King Luther Capital Management Corp decreased Watsco Inc (WSO) stake by 22.02% reported in 2017Q2 SEC filing. King Luther Capital Management Corp sold 7,030 shares as Watsco Inc (WSO)’s stock declined 7.78%. The King Luther Capital Management Corp holds 24,890 shares with $3.84M value, down from 31,920 last quarter. Watsco Inc now has $5.54 billion valuation. The stock increased 0.54% or $0.91 during the last trading session, reaching $169.14. About 72,035 shares traded. Watsco, Inc. (NYSE:WSO) has risen 8.75% since December 12, 2016 and is uptrending. It has underperformed by 7.95% the S&P500.

Analysts await Blueprint Medicines Corporation (NASDAQ:BPMC) to report earnings on March, 8. They expect $-1.06 earnings per share, down 41.33% or $0.31 from last year’s $-0.75 per share. After $-0.96 actual earnings per share reported by Blueprint Medicines Corporation for the previous quarter, Wall Street now forecasts 10.42% negative EPS growth.

Among 10 analysts covering Blueprint Medicine Corp (NASDAQ:BPMC), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blueprint Medicine Corp has $99.0 highest and $15 lowest target. $77.11’s average target is -8.08% below currents $83.89 stock price. Blueprint Medicine Corp had 22 analyst reports since February 22, 2016 according to SRatingsIntel. BTIG Research maintained the stock with “Buy” rating in Monday, November 13 report. Morgan Stanley maintained the stock with “Overweight” rating in Monday, October 23 report. Wedbush maintained Blueprint Medicines Corporation (NASDAQ:BPMC) on Monday, November 6 with “Buy” rating. BTIG Research initiated the stock with “Buy” rating in Friday, September 29 report. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) has “Buy” rating given on Monday, September 4 by Jefferies. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) has “Buy” rating given on Tuesday, June 6 by Jefferies. The company was maintained on Tuesday, October 31 by BTIG Research. Goldman Sachs upgraded the stock to “Buy” rating in Monday, December 11 report. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, August 2. The rating was maintained by Canaccord Genuity on Wednesday, September 20 with “Buy”.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. The company has market cap of $3.29 billion. The Company’s lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It currently has negative earnings. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase and predicted NTRK resistant mutants.

Among 10 analysts covering Watsco (NYSE:WSO), 7 have Buy rating, 2 Sell and 1 Hold. Therefore 70% are positive. Watsco had 30 analyst reports since September 11, 2015 according to SRatingsIntel. The rating was upgraded by Longbow on Friday, October 14 to “Buy”. The rating was maintained by Morgan Stanley with “Underweight” on Thursday, October 26. The rating was maintained by Stephens with “Overweight” on Wednesday, October 28. The firm has “Underweight” rating by Morgan Stanley given on Wednesday, July 26. The firm has “Underweight” rating by Morgan Stanley given on Monday, September 25. Robert W. Baird maintained Watsco, Inc. (NYSE:WSO) rating on Thursday, April 21. Robert W. Baird has “Outperform” rating and $144 target. Barclays Capital maintained Watsco, Inc. (NYSE:WSO) on Monday, April 18 with “Underweight” rating. The stock of Watsco, Inc. (NYSE:WSO) has “Buy” rating given on Sunday, December 10 by Stifel Nicolaus. The rating was initiated by Stifel Nicolaus with “Buy” on Wednesday, November 25. Stifel Nicolaus maintained the shares of WSO in report on Friday, June 23 with “Buy” rating.

Investors sentiment increased to 1.58 in 2017 Q2. Its up 0.13, from 1.45 in 2017Q1. It is positive, as 47 investors sold WSO shares while 65 reduced holdings. 49 funds opened positions while 113 raised stakes. 28.02 million shares or 3.66% more from 27.03 million shares in 2017Q1 were reported. Thrivent Fincl For Lutherans reported 35,603 shares. Dudley & Shanley Ltd Llc accumulated 1,300 shares. Moreover, Thomaspartners has 0.8% invested in Watsco, Inc. (NYSE:WSO). The Rhode Island-based Endurance Wealth Management Inc has invested 0.01% in Watsco, Inc. (NYSE:WSO). 101 were reported by Gemmer Asset Lc. Natixis has invested 0% in Watsco, Inc. (NYSE:WSO). Kames Capital Public Limited Liability Corporation holds 0% of its portfolio in Watsco, Inc. (NYSE:WSO) for 96,704 shares. Riverhead Capital Ltd Llc reported 0.01% in Watsco, Inc. (NYSE:WSO). Loring Wolcott & Coolidge Fiduciary Advisors Limited Liability Partnership Ma holds 0.01% or 4,145 shares in its portfolio. Massmutual Trust Co Fsb Adv holds 0% or 166 shares in its portfolio. Vanguard Grp Inc Inc invested 0.02% in Watsco, Inc. (NYSE:WSO). First Republic Mgmt Incorporated stated it has 206,716 shares. Df Dent And Incorporated has invested 1.39% in Watsco, Inc. (NYSE:WSO). Winslow Evans Crocker holds 800 shares. Ing Groep Nv invested in 0.01% or 3,698 shares.

Analysts await Watsco, Inc. (NYSE:WSO) to report earnings on February, 13. They expect $1.00 EPS, up 23.46% or $0.19 from last year’s $0.81 per share. WSO’s profit will be $32.78M for 42.29 P/E if the $1.00 EPS becomes a reality. After $1.82 actual EPS reported by Watsco, Inc. for the previous quarter, Wall Street now forecasts -45.05% negative EPS growth.

King Luther Capital Management Corp increased Visa Inc (NYSE:V) stake by 8,866 shares to 688,340 valued at $64.55M in 2017Q2. It also upped Viacom Inc New (NASDAQ:VIAB) stake by 21,692 shares and now owns 342,299 shares. Pioneer Nat Res Co (NYSE:PXD) was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *